These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35611023)

  • 1. Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report.
    Sim HE; Kim JS; Hwang JH
    Case Rep Ophthalmol; 2022; 13(1):166-171. PubMed ID: 35611023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Study on Anti-VEGF in Wet Age-Related Macular Degeneration in the Setting Based on Lean Methodology from the Bari Intravitreal Injection Registry (BIVIR).
    Grassi MO; Viggiano P; Borrelli E; Boscia G; Molfetta T; Malerba MG; D'Addario M; Giancipoli E; Alessio G; Boscia F
    Ophthalmol Ther; 2024 Jun; 13(6):1619-1634. PubMed ID: 38619788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked Choroidal Thinning Observed after Intravitreal Brolucizumab Injection.
    Ueta Y; Kamada R; Watanabe Y; Tanaka N
    Case Rep Ophthalmol; 2023; 14(1):620-625. PubMed ID: 38023610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal brolucizumab as treatment of early onset radiation retinopathy secondary to plaque brachytherapy for choroidal melanoma.
    Villegas NC; Mishra K; Steinle N; Liu W; Beadle B; Mruthyunjaya P
    Am J Ophthalmol Case Rep; 2022 Sep; 27():101581. PubMed ID: 35599950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration.
    Avaylon J; Lee S; Gallemore RP
    Int Med Case Rep J; 2020; 13():145-152. PubMed ID: 32494207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab.
    Viggiano P; Grassi MO; Boscia G; Pignataro M; Petruzzella G; Borrelli E; Molfetta T; Alessio G; Boscia F
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of brolucizumab for serous drusenoid pigment epithelium detachment non-responder to bevacizumab and aflibercept.
    Saitta A; D'Eliseo LA; D'Eliseo D
    Eur J Ophthalmol; 2023 Nov; 33(6):NP109-NP112. PubMed ID: 36448189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study.
    Tamashiro T; Tanaka K; Itagaki K; Nakayama M; Maruko I; Wakugawa S; Terao N; Onoe H; Wakatsuki Y; Ogasawara M; Sugano Y; Yamamoto A; Kataoka K; Izumi T; Kawai M; Mori R; Sekiryu T; Okada AA; Iida T; Koizumi H;
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1857-1865. PubMed ID: 35034215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye.
    Maggio E; Alfano A; Mete M; Pertile G
    Case Rep Ophthalmol; 2022; 13(3):736-743. PubMed ID: 36845453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study.
    Kim J; Lee SJ; Park TK; Sun HJ; Kim HD; Cho IH; Han JW; Choi KS
    Korean J Ophthalmol; 2023 Oct; 37(5):365-372. PubMed ID: 37562440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result.
    Kikushima W; Sakurada Y; Fukuda Y; Matsubara M; Kotoda Y; Sugiyama A; Kashiwagi K
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
    Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
    Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R; Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.
    Musiał-Kopiejka M; Polanowska K; Dobrowolski D; Krysik K; Wylęgała E; Grabarek BO; Lyssek-Boroń A
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.